Endocrine Abstracts

Introduction: Potent 11β-hydroxylase inhibitor osilodrostat provides cortisol level control in patients with Cushing’s syndrome (CS), as demonstrated by the LINC clinical development programme in Cushing’s disease (CD) patients.1 We report data from year 1 of the prospective observational LINC6 study (NCT05382156), evaluating long-term safety and efficacy of osilodrostat in CS patients during 3 years of routine clinical practice.<p class="abstext"...

Introduction: Subcutaneous (sc) pasireotide effectively reduces cortisol levels and is generally well tolerated in Cushing’s disease (CD) patients, as demonstrated by a Phase III study (NCT00434148). We report data from a non-interventional, multinational study (NCT02310269) evaluating long-term safety and efficacy of pasireotide sc for CD patients.Methods: Adults with CD, for whom surgery has failed or is not an option, were analysed by time of pas...